CN113750014A - 一种防脱育发组合物及其制备方法和应用 - Google Patents
一种防脱育发组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113750014A CN113750014A CN202111198464.4A CN202111198464A CN113750014A CN 113750014 A CN113750014 A CN 113750014A CN 202111198464 A CN202111198464 A CN 202111198464A CN 113750014 A CN113750014 A CN 113750014A
- Authority
- CN
- China
- Prior art keywords
- hair
- hair loss
- parts
- extract
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 230000003656 anti-hair-loss Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 210000004209 hair Anatomy 0.000 claims abstract description 33
- 230000003779 hair growth Effects 0.000 claims abstract description 33
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims abstract description 32
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims abstract description 32
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims abstract description 32
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229940100243 oleanolic acid Drugs 0.000 claims abstract description 32
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims abstract description 32
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 claims abstract description 30
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 claims abstract description 30
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 claims abstract description 30
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 claims abstract description 30
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 claims abstract description 30
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 27
- 230000001737 promoting effect Effects 0.000 claims abstract description 12
- 201000004384 Alopecia Diseases 0.000 claims description 67
- 239000000284 extract Substances 0.000 claims description 57
- 208000024963 hair loss Diseases 0.000 claims description 41
- 230000003676 hair loss Effects 0.000 claims description 40
- 241000382455 Angelica sinensis Species 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 241000949456 Zanthoxylum Species 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 11
- 229940013368 zanthoxylum bungeanum fruit extract Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 235000007650 Aralia spinosa Nutrition 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002453 shampoo Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 229940051250 hexylene glycol Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 29
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 24
- 210000003780 hair follicle Anatomy 0.000 abstract description 17
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 12
- 230000002757 inflammatory effect Effects 0.000 abstract description 11
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 8
- 229960003604 testosterone Drugs 0.000 abstract description 6
- 108010080146 androgen receptors Proteins 0.000 abstract description 4
- 230000003778 catagen phase Effects 0.000 abstract description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102100032187 Androgen receptor Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000004761 scalp Anatomy 0.000 description 11
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 231100000360 alopecia Toxicity 0.000 description 8
- 229960003473 androstanolone Drugs 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 3
- 102000001307 androgen receptors Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000576429 Forsythia suspensa Species 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229940095673 shampoo product Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- VFKZECOCJCGZQK-UHFFFAOYSA-M 3-hydroxypropyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CCCO VFKZECOCJCGZQK-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N Epristeride Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 241000931143 Gleditsia sinensis Species 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 235000015912 Impatiens biflora Nutrition 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 240000003377 Shepherdia canadensis Species 0.000 description 1
- 235000018324 Shepherdia canadensis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000009188 angelicae sinensis extract Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000036621 balding Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229950009537 epristeride Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003721 exogen phase Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940035650 rheum palmatum root extract Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229940084750 sophora flavescens root extract Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cosmetics (AREA)
Abstract
本发明提供一种防脱育发组合物及其制备方法和应用。所述防脱育发组合物包括:甘草苷、齐墩果酸、当归提取液和花椒果提取液。这四种组分相互配合协同增效,从而有效抑制5α‑还原酶活性,极大程度上避免5α‑还原酶催化睾酮转化为DHT,继而避免高活性的DHT与雄激素受体结合后作用于毛囊产生的快速进入退行期、微型化、毛发脱落等问题;同时,所述防脱育发组合物还能够抑制因皮肤毛囊中的IL‑1β、TNF‑α炎症因子的表达,从而最终达到防脱发、促进毛发生长的目的。
Description
技术领域
本发明属于化妆品技术领域,具体涉及一种防脱育发组合物及其制备方法和应用。
背景技术
头发是人体的附属器,是人体的重要组成部分,具有保护、修饰以及其他生理功能。而脱发是一种以毛发减少为特征的皮肤疾病。脱发导致头发稀疏或过早秃顶,都会影响美观,给患者带来很多烦恼和痛苦,影响人们正常的工作和生活,甚至还会摧残患者的心理健康,打击人的自信心,头发的健康养护防止脱发已经是人们迫在眉睫要解决的问题。
而就脱发而言,最大的引起因素之一是皮脂腺分泌异常。针对皮脂腺分泌异常,医学上一般是针对雄性激素过多,采用增加雌性激素调节或者使用一些针对雄性激素导致皮脂腺分泌异常的药物例如西咪替酊减少雄性激素分泌,还有使用非那雄胺、度他雄胺和依立雄胺来抑制5α-还原酶。然而,调节激素药物的使用对身体都有不同的伤害。因此,现有技术中的5α-还原酶抑制药物的安全性还有待提高。而对于油性肌肤的护理,最主要做到清洁干净彻底,油脂分泌得到控制,使肌肤尽量处于水油平衡的状态。与此同时,做好抗炎和抑菌工作,能够更有效的协助预防并控制痤疮和脂溢性皮炎等皮肤疾病。
CN105232410A公开了一种控油防脱的洗发产品及其制备方法,该产品由如下物质组成:月桂酰小麦氨基酸钾、椰油酰胺丙基甜菜碱、无患子果皮提取物、油茶籽提取物、皂荚提取物、人参根提取物、苦参根提取物、王不留行提取物、桑叶提取物、透骨草提取物、甘草根提取物、红花花提取物、掌叶大黄根提取物甜菜碱、泛醇、尿囊素、水解胶原、羟丙基瓜儿胶羟丙基三甲基氯化铵、玉兰花油、防腐剂和水。该控油防脱洗发产品可减少头皮油脂分泌,减少头发脱落,然而在预防脱发及控制痤疮和脂溢性皮炎等皮肤疾病方面效果不佳。
CN113116960A公开了一种治疗脱发的组合物及其制备方法,该中药组合物由以下原料制备而成:水提液、醇提液、VC1、VE1、黄芩苷、齐墩果酸、甘草酸、茶多酚、薄荷脑、冰片。该发明能一定程度上补充发根所需营养,激发毛囊活性,促进黑发生长,适用于青少年脱发,青、中年女性头发稀疏;中老年脱发及华发稀疏者,然而同样地在预防脱发及控制痤疮和脂溢性皮炎等皮肤疾病方面效果不佳。
因此,开发一种从根源上解决并从根本上预防脱发问题的头部护理产品是本领域的研究重点。
发明内容
针对现有技术的不足,本发明的目的在于提供一种防脱育发组合物及其制备方法和应用。所述防脱育发组合物通过抑制5α-还原酶活性进而达到控油、抑制炎症因子进而达到抗炎抑菌的效果,可实现头皮水油平衡,有效修复头皮屏障功能,从而从根源上解决和预防脱发问题。
为达此目的,本发明采用以下技术方案:
第一方面,本发明提供一种防脱育发组合物,所述防脱育发组合物包括:甘草苷、齐墩果酸、当归提取液和花椒果提取液。
在本发明中,所述甘草苷、齐墩果酸、当归提取液和花椒果提取液相互配合,具有协同增效的作用,能够有效抑制5α-还原酶活性,极大程度上避免5α-还原酶催化睾酮转化为DHT,继而避免高活性的DHT与雄激素受体结合后作用于毛囊产生的快速进入退行期、微型化、毛发脱落等问题;同时,本发明所述防脱育发组合物还能够抑制因皮肤毛囊中的IL-1β、TNF-α炎症因子的表达,从而最终达到防脱发、促进毛发生长的目的。此外,甘草苷、齐墩果酸、当归提取液和花椒果提取液相互配合,还能进一步提高平衡头皮油脂、减少头屑、杀菌抑菌的能力。
在本发明中,甘草苷能够抑制消化性溃疡的发生,并防止少白头和脱发,添加到护发防脱育发组合物中,在消炎抑菌、散结解表的同时能显著提高防脱效果;齐墩果酸能够抑制5α-还原酶活性进而达到控油效果,能够表现出控油起效快、控油时间长不易反复的优势;当归提取液主要成分是当归多糖,赋予头皮营养物质,改善头皮营养运输,从而恢复头皮表皮、真皮、皮下组织细胞功能,实现头皮健康全方位护理;花椒果提取液性味辛温,温中止痛,杀虫止痒。
优选地,所述防脱育发组合物按重量份数计包括:甘草苷0.01-5份、齐墩果酸0.01-5份、当归提取液1-15份和花椒果提取液1-15份。
在所述防脱育发组合物中,甘草苷的含量为0.01-5份,例如可以是0.01份、0.02份、0.05份、0.08份、0.1份、0.2份、0.3份、0.4份、0.5份、0.6份、0.7份、0.8份、0.9份、1份、1.5份、2份、2.5份、3份、3.5份、4份、4.5份、5份等。
在所述防脱育发组合物中,齐墩果酸的含量为0.01-5份,例如可以是0.01份、0.05份、0.1份、0.2份、0.3份、0.4份、0.5份、0.6份、0.8份、1份、1.2份、1.4份、1.6份、1.8份、2份、2.5份、3份、3.5份、4份、4.5份、5份等。
在所述防脱育发组合物中,当归提取液的含量为1-15份,例如可以是1份、2份、3份、4份、5份、6份、7份、8份、9份、10份、11份、12份、13份、14份、15份等。
在所述防脱育发组合物中,花椒果提取液的含量为1-15份,例如可以是1份、2份、3份、4份、5份、6份、7份、8份、9份、10份、11份、12份、13份、14份、15份等。
优选地,所述防脱育发组合物按重量份数计包括:甘草苷0.5-1.5份、齐墩果酸0.5-1.5份、当归提取液8-12份和花椒果提取液3-8份。
在本发明中,各组分优选上述比例范围内,能够进一步提高平衡头皮油脂、减少头屑、杀菌抑菌、防脱发的能力。
优选地,所述防脱育发组合物还包括溶剂。
优选地,所述溶剂的添加量占所述防脱育发组合物总质量的50-90%,例如可以是50%、55%、60%、65%、70%、75%、80%、85%、90%等。
优选地,所述溶剂为醇和水的混合溶液。
优选地,所述醇和水的质量比为1:(1-2),例如可以是1:1、1:1.1、1:1.2、1:1.3、1:1.4、1:1.5、1:1.6、1:1.7、1:1.8、1:1.9、1:2等。
优选地,所述醇包括乙醇、异戊二醇、辛甘醇、丙二醇、丁二醇、己二醇或甘油中的任意一种或至少两种的组合,优选为丁二醇和/或己二醇。
在本发明中,选择适当比例的特定醇和水的混合溶液进行稀释,还能进一步提高所述防脱育发组合物中各功效成分自身能力的发挥,使得所述组合物的控油、抗炎抑菌的能力得到进一步地提高,能够更好地解决和预防脱发问题。
优选地,所述防脱育发组合物按质量百分含量计由如下组分组成:甘草苷0.01-5%、齐墩果酸0.01-5%、当归提取液1-15%、花椒果提取液1-15%、丁二醇5-15%和己二醇15-25%,余量为水。
以所述防脱育发组合物总质量为100%计,甘草苷的含量为0.01-5%,例如可以是0.01%、0.05%、0.1%、0.2%、0.3%、0.4%、0.5%、0.6%、0.7%、0.8%、0.9%、1%、1.5%、2%、2.5%、3%、3.5%、4%、4.5%、5%等。
以所述防脱育发组合物总质量为100%计,齐墩果酸的含量为0.01-5%,例如可以是0.01%、0.05%、0.1%、0.15%、0.2%、0.25%、0.3%、0.35%、0.4%、0.45%、0.5%、0.6%、0.8%、1%、1.2%、1.4%、1.6%、1.8%、2%、2.5%、3%、3.5%、4%、4.5%、5%等。
以所述防脱育发组合物总质量为100%计,当归提取液的含量为1-15%,例如可以是1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%等。
以所述防脱育发组合物总质量为100%计,花椒果提取液的含量为1-15%,例如可以是1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%等。
以所述防脱育发组合物总质量为100%计,丁二醇的含量为5-15%,例如可以是5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%等。
以所述防脱育发组合物总质量为100%计,己二醇的含量为15-25%,例如可以是15%、16%、18%、20%、22%、24%、25%等。
优选地,所述防脱育发组合物按质量百分含量计由如下组分组成:甘草苷0.1-0.8%、齐墩果酸0.5-1.5%、当归提取液8-12%和花椒果提取液3-8%、丁二醇5-15%和己二醇15-25%,余量为水。
第二方面,本发明提供一种如第一方面的防脱育发组合物的制备方法,所述防脱育发组合物的制备方法包括:将甘草苷、齐墩果酸、当归提取液和花椒果提取液溶解,过滤,得到所述防脱育发组合物。
优选地,所述溶解的温度为10-40℃,例如可以是10℃、20℃、25℃、30℃、40℃等,所述溶解的时间为1-20min,例如可以是1min、5min、10min、15min、20min等。
优选地,所述过滤采用300-500目(例如可以是300目、350目、400目、450目、500目等)的滤布进行。
优选地,所述防脱育发组合物的制备方法包括:将甘草苷、齐墩果酸、当归提取液和花椒果提取液溶解于醇和水的混合溶液中,在10-40℃下混合搅拌1-20min,采用300-500目的滤布进行过滤,得到所述防脱育发组合物。
第三方面,本发明提供一种如第一方面所述的防脱育发组合物在制备化妆品中的应用。
第四方面,本发明提供一种化妆品,所述化妆品包括如第一方面所述的防脱育发组合物。
优选地,所述化妆品包括洗发水、洗发膏、精华液或护发素中的任意一种或至少两种的组合。
优选地,所述防脱育发组合物的添加量占所述化妆品总质量的1-20%,例如可以是1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%等。
相对于现有技术,本发明具有以下有益效果:
(1)本发明所述防脱育发组合物通过甘草苷、齐墩果酸、当归提取液和花椒果提取液四种有效成分的协同复配,有效抑制5α-还原酶活性,极大程度上避免5α-还原酶催化睾酮转化为DHT,继而避免高活性的DHT与雄激素受体结合后作用于毛囊产生的快速进入退行期、微型化、毛发脱落等问题;
(2)本发明所述防脱育发组合物通过甘草苷、齐墩果酸、齐墩果酸四种有效成分的协同复配,还能够抑制因皮肤毛囊中的IL-1β、TNF-α炎症因子的表达,从而最终达到防脱发、促进毛发生长的目的;
(3)本发明所述防脱育发组合物可以预防并改善脱发的情况,保持皮层卫生、透气、不油腻,收敛过度肥大的皮脂腺,具有减少皮脂分泌和促进血液循环的作用,对于已脱落的头发毛孔具有清理、刺激作用。
具体实施方式
下面通过具体实施方式来进一步说明本发明的技术方案。本领域技术人员应该明了,所述实施例仅仅是帮助理解本发明,不应视为对本发明的具体限制。
以下实施例和对比例各组分来源如下所示:
下述实施例和对比例中当归提取液的质量比为②:③=5:3
实施例1
本实施例提供一种防脱育发组合物,以所述防脱育发组合物总质量为100%计,所述防脱育发组合物按质量百分含量计由如下组分组成:
所述防脱育发组合物的制备方法包括:按上述配方量将甘草苷、齐墩果酸、齐墩果酸、当归提取液、花椒果提取液、苦参提取液和连翘提取液溶解于醇和水的混合溶液中,25℃混合搅拌5min,采用500目的滤布过滤,得到所述防脱育发组合物。
实施例2
本实施例提供一种防脱育发组合物,以所述防脱育发组合物总质量为100%计,所述防脱育发组合物按质量百分含量计由如下组分组成:
所述防脱育发组合物的制备方法包括:按上述配方量将甘草苷、齐墩果酸、齐墩果酸、当归提取液、花椒果提取液、苦参提取液和连翘提取液溶解于醇和水的混合溶液中,30℃混合搅拌3min,采用500目的滤布过滤,得到所述防脱育发组合物。
实施例3
本实施例提供一种防脱育发组合物,以所述防脱育发组合物总质量为100%计,所述防脱育发组合物按质量百分含量计由如下组分组成:
所述防脱育发组合物的制备方法包括:按上述配方量将甘草苷、齐墩果酸、齐墩果酸、当归提取液、花椒果提取液、苦参提取液和连翘提取液溶解于醇和水的混合溶液中,35℃混合搅拌1min,采用500目的滤布过滤,得到所述防脱育发组合物。
实施例4
本实施例提供一种防脱育发组合物,以所述防脱育发组合物总质量为100%计,所述防脱育发组合物按质量百分含量计由如下组分组成:
所述防脱育发组合物的制备方法同实施例1。
实施例5
本实施例提供一种防脱育发组合物,以所述防脱育发组合物总质量为100%计,所述防脱育发组合物按质量百分含量计由如下组分组成:
所述防脱育发组合物的制备方法同实施例1。
对比例1-4
对比例1-4提供四种防脱育发组合物,与实施例1的区别在于,仅含甘草苷、齐墩果酸、当归提取液或花椒果提取液中一种成分;各例防脱育发组合物按质量百分含量计由如下组分组成:
对比例5-8
对比例5-8提供四种防脱育发组合物,与实施例1的区别在于,缺少甘草苷、齐墩果酸、当归提取液或花椒果提取液中任意一种成分;各例防脱育发组合物按质量百分含量计由如下组分组成:
试验例1
5α还原酶活性抑制率测试
测试样品:实施例1-5和对比例1-8制备得到的防脱育发组合物;
测试方法:具体包括以下步骤:
(1)5α还原粗酶的制备:
用10%水合氯醛腹腔过量注射处死雄性SD大鼠,迅速解剖取出肝脏组织,用生理盐水冲洗去多余血液,按质量比1:5比例加入磷酸缓冲液(pH=7.4),加入磁珠在匀浆机中匀浆,取匀浆于冷冻离心机上4℃10000r/min离心10min,取上清重复离心一次,将上清液即为粗酶液,于-20℃冻存备用。
(2)蛋白含量测定:
用蛋白定量试剂盒测定粗酶液中蛋白浓度,根据试剂盒提供实验方法将蛋白标准品稀释质量浓度为0,10,20,40,80,120,160,200μg/mL系列标准蛋白质溶液。向上述各系列标准溶液中加入G250染色液200μL,混匀后室温放置3-5min后,用酶标仪于波长595nm处检测其吸光度,以蛋白吸光度(Y)为纵坐标,质量浓度(X,mg/mL)为横坐标绘制标准曲线。通过蛋白质标准曲线方程来计算粗酶蛋白质量浓度。
(3)5α还原酶活性抑制活性测定
5α还原酶催化反应总反应体积为200μL,120mg/mL肝脏匀浆液、5mg/mL NADPH、0.2mg/mL睾酮及不同浓度待测样品。
空白组测定:于96孔板中加入肝脏匀浆液120μL、5mg/mL NADPH 60μL、0.2mg/mL睾酮10μL、磷酸缓冲液(pH 7.4)10μL、充分混合后测定吸光度A0,37℃恒温孵育60min后测定吸光度A1,得到NADPH变化值△A0。
样品组测定:分别配制不同浓度待测样品待测液(2,5,10,20,30,40mg/mL),分别进行反应得到NADPH变化值△An。
阳性组测定:以非那雄胺为阳性对照药,按照上述方法判断酶的活性是否被抑制,且初步计算抑制率的大小。
计算公式为I%=(△An-△Ao)/△Ao×100%。实验重复3次,每次3个平行样本。
具体测试结果如表1所示(其中,以代号C8代表防脱育发组合物,DPO代表二氨基嘧啶氧化物,且均以水进行稀释补至100%):
表1
由表1测试结果可知,100wt%的所述防脱育发组合物对5α还原酶活性的抑制率高达190%以上,充分说明本发明通过甘草苷、齐墩果酸、当归提取液和花椒果提取液四种有效成分的协同复配,达到深入头皮和毛囊中,抑制5α-还原酶活性的目的。同时,四者复配,还能极大程度上避免5α-还原酶催化睾酮转化为DHT,继而避免高活性的DHT与雄激素受体结合。
此外,在稀释实验中发现,在纯水溶液、乙醇溶液、或乙醇+DPO中,均随着浓度的增加,5α还原酶活性的抑制率逐渐增加。因此,本发明所述防脱育发组合物在化妆品适宜在占所述化妆品总质量的15%左右(如14-20%范围内),既能达到高5α还原酶活性的抑制率。
同时,不难发现额外添加乙醇和二氨基嘧啶氧化物能进一步地提高在任一浓度时,组合物对5α还原酶活性的抑制率,使其基本可以达到和100wt%的C8相当的抑制率,因此选择该方案可以避免添加量过多带来的弊端和浪费。
试验例2
炎症因子抑制率测试
测试样品:实施例1-5和对比例1-8制备得到的防脱育发组合物;
测试方法:利用脂多糖(LPS)分别刺激给药组与空白组的人永生化角质形成细胞(HaCaT细胞),通过ELISA检测给药组预处理组与对照组的HaCaT细胞上清液中相关炎症因子白介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)的蛋白表达。
将HaCaT细胞常规培养于含10%(体积分数)胎牛血清的DMEM完全培养基(添加1%双抗:青霉素100U/mL和链霉素100μg/mL)中,培养条件为37℃、5%(体积分数)CO2、饱和湿度培养箱中,每2-3天换液一次,3-7天传代一次。取对数生长期HaCaT细胞,用0.25%胰蛋白酶-EDTA对细胞进行消化10min,清洗细胞后向细胞沉淀中加入完全培养基,轻柔吹打成细胞悬液。用新鲜培养液调整细胞浓度为4×104个/孔,将细胞接种于24孔板上,细胞培养箱中孵育24h,细胞贴壁约达60%-70%后加LPS。设置空白组、脂多糖LPS 20μg/mL刺激24h组、不同给药组预处理24h+LPS 20μg/mL刺激24h组,每组各设置5个复孔,刺激结束后吸取每孔细胞上清液分装至1.5mLEP管中,可立即使用或-20℃冻存备用。用ELISA试剂盒方法(江苏酶标生物科技有限公司)测试其上清测试TNF-α和IL-1β的表达量。
具体测试结果如表2所示:
表2
由表2测试数据可知,本发明所述防脱育发组合物对炎症因子的生成有很好地抑制效果,使用后炎症因子IL-β的含量降至106以下,炎症因子TNF-α含量降至110以下。充分说明,本发明通过甘草苷、齐墩果酸、当归提取液和花椒果提取液三种有效成分的协同复配,能够起到抑制因皮肤毛囊中的过度表达的IL-1β、TNF-α2炎症因子,起到高效抗炎的作用。
试验例3
小鼠实验
测试样品:实施例1-5和对比例1-8制备得到的防脱育发组合物;
测试方法:将C57小鼠(雄性,5周龄)饲养于温度(23±2)℃,湿度(54±10)%环境,自由饮食、饮水。除空白组外,均选小鼠背部给与药物皮下注射,均予以注射丙酸睾酮5mg/kg·d,4周建模成功后进行给药,模型组及空白组涂抹生理盐水,米诺地尔组涂抹5%米诺地尔酊0.2mL/d,样品组涂抹对应15wt%的组合物C8的水溶液,每日1次,周期4周。
(1)终毛/毳毛值比值:实验第8周结束观察后,处死小鼠,取各组小鼠背部脱发区皮肤约1cm×1cm后平整的贴于固定板上,进行石蜡切片脱蜡、苏木精-伊红染色、脱水封片实验操作,在100倍显微镜视野下,平均3个不重叠的视野下,观察小鼠毛囊形态学变化,利用Image-Pro Plus测量毛囊长度及其大小,统计生长期毛囊数量与休止期毛囊数量比值(A/T);
(2)ELISA测定皮肤组织中二氢睾酮(DHT)和5α还原酶的含量:将各组小鼠经解剖采集的组织,制备组织匀浆,按ELISA试剂盒说明书上的方法用Elisa试剂盒测定每组样品中DHT和5α-还原酶含量,记录数据,使用Excel,求其均值;
(3)免疫组化测定皮肤中TGF-β1和TNF-α的含量:每组每只小鼠取材2.0cm×0.8cm长条状皮肤,置生理盐水中充分漂洗残余血液,铺展于滤纸上,室温晾干,用锡箔纸上包好,按照Anti-TGFB1与TNF-α的使用方法进行免疫组化检测测定小鼠皮肤中TGF-β1和TNF-α的含量的实验,记录数据,使用Excel,求其均值;
具体测试结果如表3所示:(其中,以代号C8代表防脱育发组合物):
表3
由表3测试数据可知,使用本发明所述防脱发组合物后,相比模型组小鼠背部受试区组织HE染色结果的终毛/毳毛值比值明显上升,增至4以上;ELISA测定皮肤组织中二氢睾酮(DHT)和5α还原酶的含量明显下降,免疫组化测定皮肤中TGF-β1和TNF-α的含量明显下降。由此充分说明本发明通过甘草苷、齐墩果酸、当归提取液和花椒果提取液四种有效成分的协同复配,能够有效深入头皮和毛囊中,有效抑制5α-还原酶,改善DHT引起的毛囊萎缩;同时抑制因皮肤毛囊中的厌氧菌痤疮杆菌滋生而过度表达的IL-1β、TNF-α炎症因子,能够实现标本兼治共同发挥控油和抗炎作用,从根本上改善毛囊微循环,刺激细胞新陈代谢,从根源上解决脱发问题。
申请人声明,本发明通过上述实施例来说明本发明的防脱育发组合物及其制备方法和应用,但本发明并不局限于上述实施例,即不意味着本发明必须依赖上述实施例才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (10)
1.一种防脱育发组合物,其特征在于,所述防脱育发组合物包括:甘草苷、齐墩果酸、当归提取液和花椒果提取液。
2.根据权利要求1所述的防脱育发组合物,其特征在于,所述防脱育发组合物按重量份数计包括:甘草苷0.01-5份、齐墩果酸0.01-5份、当归提取液1-15份和花椒果提取液1-15份。
3.根据权利要求1或2所述的防脱育发组合物,其特征在于,所述防脱育发组合物按重量份数计包括:甘草苷0.5-1.5份、齐墩果酸0.5-1.5份、当归提取液8-12份和花椒果提取液3-8份。
4.根据权利要求1-4中任一项所述的防脱育发组合物,其特征在于,所述防脱育发组合物还包括溶剂;
优选地,所述溶剂的添加量占所述防脱育发组合物总质量的50-90%;
优选地,所述溶剂为醇和水的混合溶液;
优选地,所述醇和水的质量比为1:(1-2);
优选地,所述醇包括乙醇、异戊二醇、辛甘醇、丙二醇、丁二醇、己二醇或甘油中的任意一种或至少两种的组合,优选为丁二醇和/或己二醇。
5.根据权利要求1-4中任一项所述的防脱育发组合物,其特征在于,所述防脱育发组合物按质量百分含量计由如下组分组成:甘草苷0.01-5%、齐墩果酸0.01-5%、当归提取液1-15%、花椒果提取液1-15%、丁二醇5-15%和己二醇15-25%,余量为水。
6.根据权利要求1-5中任一项所述的防脱育发组合物,其特征在于,所述防脱育发组合物按质量百分含量计由如下组分组成:甘草苷0.1-0.8%、齐墩果酸0.5-1.5%、当归提取液8-12%和花椒果提取液3-8%、丁二醇5-15%和己二醇15-25%,余量为水。
7.根据权利要求1-6中任一项所述的防脱育发组合物的制备方法,其特征在于,所述防脱育发组合物的制备方法包括:将甘草苷、齐墩果酸、当归提取液和花椒果提取液溶解,过滤,得到所述防脱育发组合物。
8.根据权利要求7所述的防脱育发组合物的制备方法,其特征在于,所述溶解的温度为10-40℃,所述溶解的时间为1-20min;
优选地,所述过滤采用300-500目的滤布进行;
优选地,所述防脱育发组合物的制备方法包括:将甘草苷、齐墩果酸、当归提取液和花椒果提取液溶解于醇和水的混合溶液中,在10-40℃下混合搅拌1-20min,采用300-500目的滤布进行过滤,得到所述防脱育发组合物。
9.根据权利要求1-6中任一项所述的防脱育发组合物在制备化妆品中的应用。
10.一种化妆品,其特征在于,所述化妆品包括权利要求1-6中任一项所述的防脱育发组合物;
优选地,所述化妆品包括洗发水、洗发膏、精华液或护发素中的任意一种或至少两种的组合;
优选地,所述防脱育发组合物的添加量占所述化妆品总质量的1-20%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111198464.4A CN113750014B (zh) | 2021-10-14 | 2021-10-14 | 一种防脱育发组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111198464.4A CN113750014B (zh) | 2021-10-14 | 2021-10-14 | 一种防脱育发组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113750014A true CN113750014A (zh) | 2021-12-07 |
CN113750014B CN113750014B (zh) | 2023-10-31 |
Family
ID=78799473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111198464.4A Active CN113750014B (zh) | 2021-10-14 | 2021-10-14 | 一种防脱育发组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113750014B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024052756A1 (en) * | 2022-09-09 | 2024-03-14 | Crodarom | Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use. |
FR3139466A1 (fr) * | 2022-09-09 | 2024-03-15 | Crodarom | Utilisation d’un extrait de poivrier de Sichuan pour un traitement cutané et une composition adaptée à cette utilisation. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050014478A (ko) * | 2003-07-31 | 2005-02-07 | 소망화장품주식회사 | 홍삼, 당약, 천궁, 목단피 및 범부채를 함유하는 두피 및모발 개선용 조성물 |
CN104127687A (zh) * | 2013-05-03 | 2014-11-05 | 吕刚 | 一种外用药膏组合物在制备用于预防、缓解和/或治疗炎症性疾病药物中的应用 |
CN105878529A (zh) * | 2016-05-20 | 2016-08-24 | 于学军 | 一种针对淋巴瘤化疗后感染的药物及其制备方法 |
KR20200137526A (ko) * | 2019-05-30 | 2020-12-09 | 조애란 | 탈모 예방 및 발모 촉진용 조성물 |
-
2021
- 2021-10-14 CN CN202111198464.4A patent/CN113750014B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050014478A (ko) * | 2003-07-31 | 2005-02-07 | 소망화장품주식회사 | 홍삼, 당약, 천궁, 목단피 및 범부채를 함유하는 두피 및모발 개선용 조성물 |
CN104127687A (zh) * | 2013-05-03 | 2014-11-05 | 吕刚 | 一种外用药膏组合物在制备用于预防、缓解和/或治疗炎症性疾病药物中的应用 |
CN105878529A (zh) * | 2016-05-20 | 2016-08-24 | 于学军 | 一种针对淋巴瘤化疗后感染的药物及其制备方法 |
KR20200137526A (ko) * | 2019-05-30 | 2020-12-09 | 조애란 | 탈모 예방 및 발모 촉진용 조성물 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024052756A1 (en) * | 2022-09-09 | 2024-03-14 | Crodarom | Use of an extract of sichuan pepper for a skin treatment and a composition suitable for this use. |
FR3139466A1 (fr) * | 2022-09-09 | 2024-03-15 | Crodarom | Utilisation d’un extrait de poivrier de Sichuan pour un traitement cutané et une composition adaptée à cette utilisation. |
FR3139467A1 (fr) * | 2022-09-09 | 2024-03-15 | Crodarom | Utilisation d’un extrait de poivrier de Sichuan pour un traitement cutané et une composition adaptée à cette utilisation. |
Also Published As
Publication number | Publication date |
---|---|
CN113750014B (zh) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113908091B (zh) | 一种防脱育发组合物及其制备方法和应用 | |
KR20070041890A (ko) | 모발 성장 촉진용 외용제 조성물 | |
CN113750014A (zh) | 一种防脱育发组合物及其制备方法和应用 | |
KR101208012B1 (ko) | 홍삼 먹인 달팽이 점액을 함유하는 화장료 조성물 및 그 제조방법 | |
US20140356468A1 (en) | Composition containing paper mulberry extracts | |
KR101690760B1 (ko) | 피부자극완화, 탈모방지 및 발모촉진 효과를 나타내는 카페오일펜타펩타이드 및 이를 함유하는 탈모방지 및 발모촉진용 화장료 조성물 | |
CN112870333A (zh) | 一种改善人脱发生发的组合物、制剂及制备方法和应用 | |
KR20060095062A (ko) | 모발 성장 촉진제 조성물 | |
CN105555285A (zh) | 用于促进生发及毛发生长的组合物 | |
WO2005076757A2 (en) | Hair and eyebrow, eyelashes growth stimulater | |
KR20140145278A (ko) | 피부 수렴 및 탄력 효과를 갖는 승마 추출물, 산수유 추출물 및 현초 추출물을 함유하는 화장료 조성물. | |
CN110064039B (zh) | 一种防脱育发组合物及其应用 | |
EP2786747B1 (en) | Promoting hair growth solution containing chlorine dioxide preparation method and use method thereof | |
JP2014185131A (ja) | 育毛剤及び育毛用頭髪化粧料 | |
KR20130036984A (ko) | 탈모방지 또는 모발 성장 촉진용 화장료 조성물 | |
CN113750013B (zh) | 一种防脱育发组合物及其制备方法和应用 | |
CN111939191B (zh) | 一种促毛囊周围血管生成和/或促毛发生长的组合物及应用 | |
KR100992414B1 (ko) | 무화과나무 잎 추출물을 함유하는 탈모방지 또는발모촉진용 화장료 조성물 | |
JP2014185130A (ja) | 育毛用頭髪化粧料 | |
KR20140126891A (ko) | 진세노사이드 Rf를 함유하는 피부 외용제 조성물 | |
CN108653144B (zh) | 一种美白化妆品 | |
KR20080011970A (ko) | 푸에라리아 속 식물추출물을 함유하는 탈모방지 또는발모촉진용 조성물 | |
KR20090022224A (ko) | 두피보호 및 모발생장을 촉진하는 화장료 조성물 | |
KR20120046564A (ko) | 천련자 추출물을 유효성분으로 함유하는 발모 및 두피 관리용 조성물 | |
JP2019206490A (ja) | 5α−リダクターゼ阻害作用を有する混合成分、及びこれを含む育毛用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |